Expansion opportunities MSNPI has expanded facilities to Green, Ohio, signaling capacity growth and potential for scale-up collaborations, contract manufacturing, and large-volume supply agreements in the US market.

US manufacturing base With a state-of-the-art facility in Piscataway, New Jersey and recent US expansion, MSNPI is well-positioned to pursue US regulatory-ready finished dosage manufacturing and strategic partnerships for generic and complex formulations.

IP and risk awareness Ongoing patent infringement litigation involving Entresto generic versions indicates a need for diligent freedom-to-operate assessments, risk-managed R&D, and targeted opportunities in non-patented or alternative therapeutic areas.

Strategic partnerships Recent collaboration with educational institutions and government-backed ventures in India suggests a capability and openness to co-development, outsourcing, and technology transfer deals that could be mirrored with US CRO/CMO partners.

Diverse capabilities MSNPI’s large product portfolio, robust R&D, and ability to handle high-volume commercial manufacturing position it for multi-SKUs supply arrangements, private-label opportunities, and regional market expansion in regulatory markets beyond the US.